Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial

Fineline Cube May 16, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors

Fineline Cube May 16, 2024

China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...

Company Deals Medical Device

GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment

Fineline Cube May 16, 2024

GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent...

Company Deals Medical Device

Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics

Fineline Cube May 16, 2024

Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+...

Company Deals

Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets

Fineline Cube May 16, 2024

Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...

Company Deals Hospital

Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China

Fineline Cube May 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion...

Company Drug

Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch

Fineline Cube May 15, 2024

Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...

Company Deals

Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round

Fineline Cube May 15, 2024

China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...

Company Policy / Regulatory

US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports

Fineline Cube May 15, 2024

The US Office of the Trade Representative (USTR) has announced a series of stringent new...

Company

Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation

Fineline Cube May 15, 2024

Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...

Company Drug

Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod

Fineline Cube May 15, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China

Fineline Cube May 15, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...

Company Drug

Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy

Fineline Cube May 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication

Fineline Cube May 15, 2024

GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...

Company Drug

Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar

Fineline Cube May 15, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...

Policy / Regulatory

China Launches Nationwide Unannounced Inspections of Medical Insurance Funds

Fineline Cube May 15, 2024

An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...

Company Drug

Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials

Fineline Cube May 15, 2024

At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...

Company Drug

RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial

Fineline Cube May 15, 2024

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...

Company Drug

Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth

Fineline Cube May 15, 2024

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024,...

Company Drug

Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial

Fineline Cube May 15, 2024

Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific...

Posts pagination

1 … 384 385 386 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.